Syndax Pharmaceuticals Inc Total Assets
Syndax Pharmaceuticals Inc total assets. Based on the latest financial reports, Syndax Pharmaceuticals Inc (SNDX) holds total assets worth $703.65 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Syndax Pharmaceuticals Inc (SNDX) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Syndax Pharmaceuticals Inc (2011–2025)
Total assets of Syndax Pharmaceuticals Inc from 2011 to 2025. This chart illustrates how Syndax Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See latest Syndax Pharmaceuticals Inc stock price today for real-time trading data and today's change.
Syndax Pharmaceuticals Inc - Asset Composition Analysis
Syndax Pharmaceuticals Inc Total Assets Breakdown (December 2025)
Syndax Pharmaceuticals Inc total assets breakdown as of December 2025. Syndax Pharmaceuticals Inc's total assets of $703.65 Million consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 25.5% |
| Accounts Receivable | $70.29 Million | 13.3% |
| Inventory | $32.75 Million | 6.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Syndax Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore SNDX working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Syndax Pharmaceuticals Inc's current assets represent 99.7% of total assets in 2025, an increase from 91.8% in 2011.
- Cash Position: Cash and equivalents constituted 25.5% of total assets in 2025, down from 77.3% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 13.3% of total assets.
Syndax Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Syndax Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
Syndax Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.77 | 4.71 | 8.30 |
| Quick Ratio | 6.44 | 4.55 | 8.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $575.36 Million | $418.69 Million | $209.54 Million |
Syndax Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Syndax Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 111.30 |
| Latest Market Cap to Assets Ratio | 2.21 |
| Asset Growth Rate (YoY) | -26.9% |
| Total Assets | $529.71 Million |
| Market Capitalization | $1.17 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Syndax Pharmaceuticals Inc's assets at a significant premium (2.21x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Syndax Pharmaceuticals Inc's assets decreased by 26.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Syndax Pharmaceuticals Inc (2011–2025)
The table below shows the annual total assets of Syndax Pharmaceuticals Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $529.71 Million | -26.92% |
| 2024-12-31 | $724.82 Million | +18.26% |
| 2023-12-31 | $612.88 Million | +23.26% |
| 2022-12-31 | $497.24 Million | +10.58% |
| 2021-12-31 | $449.66 Million | +49.58% |
| 2020-12-31 | $300.61 Million | +373.22% |
| 2019-12-31 | $63.52 Million | -24.32% |
| 2018-12-31 | $83.94 Million | -38.81% |
| 2017-12-31 | $137.19 Million | +25.84% |
| 2016-12-31 | $109.01 Million | +21.26% |
| 2015-12-31 | $89.90 Million | +601.49% |
| 2014-12-31 | $12.82 Million | -24.88% |
| 2013-12-31 | $17.06 Million | +1029.87% |
| 2012-12-31 | $1.51 Million | -68.45% |
| 2011-12-31 | $4.79 Million | -- |
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. Th… Read more